Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more
Jeil Pharmaceutical Co Ltd (271980) - Net Assets
Latest net assets as of September 2025: ₩243.59 Billion KRW
Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has net assets worth ₩243.59 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩501.66 Billion) and total liabilities (₩258.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩243.59 Billion |
| % of Total Assets | 48.56% |
| Annual Growth Rate | 3.03% |
| 5-Year Change | 27.16% |
| 10-Year Change | N/A |
| Growth Volatility | 15.13 |
Jeil Pharmaceutical Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Jeil Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jeil Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual net assets of Jeil Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩219.32 Billion | +39.66% |
| 2023-12-31 | ₩157.03 Billion | +0.92% |
| 2022-12-31 | ₩155.60 Billion | -7.02% |
| 2021-12-31 | ₩167.35 Billion | -2.98% |
| 2020-12-31 | ₩172.48 Billion | +1.43% |
| 2019-12-31 | ₩170.04 Billion | -8.05% |
| 2018-12-31 | ₩184.93 Billion | +3.90% |
| 2017-12-31 | ₩177.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jeil Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3085.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩240.45 Billion | 127.79% |
| Total Equity | ₩188.15 Billion | 100.00% |
Jeil Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
M Evo Global Acquisition Corp II Class A Ordinary Shares
NASDAQ:MEVO
|
$54.55 Million |
|
Isbir Holding AS
IS:ISBIR
|
$54.56 Million |
|
Hycon Technology
TWO:6457
|
$54.56 Million |
|
DrayTek Corp
TW:6216
|
$54.57 Million |
|
ZOOZ Strategy Ltd.
TA:ZOOZ
|
$54.54 Million |
|
Pacific Construction Co Ltd
TW:2506
|
$54.52 Million |
|
AI TRANSPORTATION ACQUISITION CORP Unit
NASDAQ:AITRU
|
$54.50 Million |
|
Raba Jarmuipari Holding Nyrt
BUD:RABA
|
$54.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jeil Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 158,570,120,020 to 188,149,813,680, a change of 29,579,693,660 (18.7%).
- Net loss of 29,967,852,430 reduced equity.
- Dividend payments of 728,378,220 reduced retained earnings.
- Other factors increased equity by 60,275,924,310.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-29.97 Billion | -15.93% |
| Dividends Paid | ₩728.38 Million | -0.39% |
| Other Changes | ₩60.28 Billion | +32.04% |
| Total Change | ₩- | 18.65% |
Book Value vs Market Value Analysis
This analysis compares Jeil Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩12106.81 | ₩14750.00 | x |
| 2018-12-31 | ₩12581.11 | ₩14750.00 | x |
| 2019-12-31 | ₩11635.35 | ₩14750.00 | x |
| 2020-12-31 | ₩11800.20 | ₩14750.00 | x |
| 2021-12-31 | ₩11515.67 | ₩14750.00 | x |
| 2022-12-31 | ₩10836.83 | ₩14750.00 | x |
| 2023-12-31 | ₩10882.20 | ₩14750.00 | x |
| 2024-12-31 | ₩12912.16 | ₩14750.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jeil Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.25%
- • Asset Turnover: 1.34x
- • Equity Multiplier: 2.79x
- Recent ROE (-15.93%) is below the historical average (-3.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.60% | 0.29% | 0.90x | 2.32x | ₩-16.73 Billion |
| 2018 | 1.02% | 0.30% | 1.56x | 2.18x | ₩-16.60 Billion |
| 2019 | -6.22% | -1.58% | 1.67x | 2.36x | ₩-27.59 Billion |
| 2020 | 4.01% | 1.00% | 1.69x | 2.38x | ₩-10.32 Billion |
| 2021 | -7.42% | -1.78% | 1.64x | 2.54x | ₩-29.29 Billion |
| 2022 | -8.29% | -1.81% | 1.58x | 2.89x | ₩-28.88 Billion |
| 2023 | 3.16% | 0.69% | 1.49x | 3.07x | ₩-10.85 Billion |
| 2024 | -15.93% | -4.25% | 1.34x | 2.79x | ₩-48.78 Billion |
Industry Comparison
This section compares Jeil Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $472,965,132,317
- Average return on equity (ROE) among peers: 3.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jeil Pharmaceutical Co Ltd (271980) | ₩243.59 Billion | 0.60% | 1.06x | $54.55 Million |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $76.07 Million |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $3.71 Billion |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $29.69 Million |
| Ildong Holdings Co Ltd (000230) | $310.17 Billion | 8.80% | 0.65x | $48.77 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $103.58 Million |
| Donga Socio Holdings (000640) | $1.03 Trillion | 5.64% | 0.91x | $204.37 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $278.79 Million |
| JW Pharmaceutical Corp (001065) | $276.31 Billion | -3.96% | 1.36x | $246.19 Million |
| Samsung Pharm (001360) | $46.24 Billion | -2.15% | 1.82x | $64.85 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $165.68 Billion | 10.17% | 0.83x | $27.46 Million |